Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans

Wang, Zijuan; Chen, Xiaofeng; Zhang, Zixiao; Li, Yuchen; Deng, Juan; Tu, Jing; Song, Zhiqiang; Zhou, Qinghua

doi:10.1016/j.micpath.2017.05.035

Cited by 39 publications

(42 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized controlled trials documented that Probiotic supplementation could reduce the incidence of adverse effects of anti‐ H. pylori eradication therapy . Additionally, Oh et al and Wang et al demonstrated that probiotic supplementation could reduce the antibiotic‐induced alteration and imbalance of the gut microbiota composition. Taken together, anti‐ H. pylori therapy can result in an increase in the relative abundance of Proteobacteria in gut microbiota, which may attribute to the development of adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Similar to the oral cavity, most gastrointestinal probiotics do not colonize or persist in the gastrointestinal tract, although there is some evidence that alterations in microbial composition may persist. [36][37][38] Despite data indicating that probiotic colonization does not persist, there are safety concerns and adverse events that should be considered, including induction of bacteremia. 37,39 Further, caution is advised when using probiotics in immunosuppressed patients or those in infirm states.…”

Section: Prob I Oti C S a S Monother Apy And Pre Ventive Ther Apymentioning

confidence: 99%

Probiotics, including nisin‐based probiotics, improve clinical and microbial outcomes relevant to oral and systemic diseases

Nguyen

Brody

Lin

et al. 2019

Periodontology 2000

View full text Add to dashboard Cite

The effects of probiotic supplementation on systemic health and gastrointestinal diseases have been investigated in numerous studies. The aim of this review is to provide an overview of probiotics and their effects on periodontal health. Probiotics show beneficial effects as adjunctive therapeutics and as stand‐alone agents in the treatment and prevention of gingivitis as well as specific clinical parameters of periodontitis. This review focuses on the clinical and microbiological aspects of probiotics in the context of health, gingivitis, and periodontitis. In addition, a special focus on nisin‐producing probiotics and nisin itself showcase their significant potential for oral and systemic use.

show abstract

“…Experimental animal studies have shown that surface proteins in probiotic strains limit the colonization of the stomach by HP (163) . Strains of Lactobacillus salivarius and L. casei may inhibit HP urease activity (by producing lactic acid) and synthesize cytokines, which are involved in inflammatory processes (164) . Therefore, these species of Lactobacilli may reduce the HP load, mucosal inflammation (by inhibiting IL-8 production), and gastric hyperacidity (165) .…”

Section: Level Of Evidence: 4 Grade Of Recommendation: Cmentioning

confidence: 99%

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Coelho

Marinho

Genta

et al. 2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the III Brazilian Consensus Conference on H. pylori infection held in 2012, in Bento Gonçalves, Brazil, and justify a fourth meeting to establish updated guidelines on the current management of H. pylori infection. Therefore, the Núcleo Brasileiro para Estudo do Helicobacter pylori e Microbiota (NBEHPM), association linked to Brazilian Federation of Gastroenterology (FBG) held its fourth meeting again in Bento Gonçalves, RS, Brazil, on August 25-27, 2017. Twenty-six delegates, including gastroenterologists, endoscopists, and pathologists from the five regions of Brazil as well as one international guest from the United States, participated in the meeting. The participants were invited based on their knowledge and contribution to the study of H. pylori infection. The meeting sought to review different aspects of treatment for infection; establish a correlation between infection, dyspepsia, intestinal microbiota changes, and other disorders with a special emphasis on gastric cancer; and reassess the epidemiological and diagnostic aspects of H. pylori infection. Participants were allocated into four groups as follows: 1) Epidemiology and Diagnosis, 2) Dyspepsia, intestinal microbiota and other afections, 3) Gastric Cancer, and, 4) Treatment. Before the consensus meeting, participants received a topic to be discussed and prepared a document containing a recent literature review and statements that should be discussed and eventually modified during the face-to-face meeting. All statements were evaluated in two rounds of voting. Initially, each participant discussed the document and statements with his group for possible modifications and voting. Subsequently, during a second voting in a plenary session in the presence of all participants, the statements were voted upon and eventually modified. The participants could vote using five alternatives: 1) strongly agree; 2) partially agree; 3) undecided; 4) disagree; and 5) strongly disagree. The adopted consensus index was that 80% of the participants responded that they strongly or partially agreed with each statement. The recommendations reported are intended to provide the most current and relevant evidences to management of H. pylori infection in adult population in Brazil.

show abstract

Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans

Cited by 39 publications

References 36 publications

Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria

Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria

Probiotics, including nisin‐based probiotics, improve clinical and microbial outcomes relevant to oral and systemic diseases

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Contact Info

Product

Resources

About